Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$81.46 USD

81.46
666,383

+0.07 (0.09%)

Updated Sep 23, 2024 04:00 PM ET

After-Market: $81.48 +0.02 (0.02%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Smith & Nephew's (SNN) CATALYSTEM System Gets FDA Clearance

by Zacks Equity Research

Smith & Nephew (SNN) announces the receipt of FDA clearance for its new CATALYSTEM Primary Hip System, which is intended to address the demands of primary hip surgery.

Moumi Mondal headshot

Pre Q3 Earnings: Is Hologic (HOLX) Stock a Portfolio Must-Have?

by Moumi Mondal

Hologic (HOLX) benefits from its unique set of businesses, each underpinned by its durable growth drivers. The impressive YTD price rally, earnings prowess and attractive valuation make the stock a top investment pick.

Hologic (HOLX) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Hologic (HOLX) closed the most recent trading day at $78.46, moving +1.45% from the previous trading session.

Stryker (SYK) Completes Artelon's Acquisition to Boost Business

by Zacks Equity Research

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific

by Zacks Equity Research

DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.

Nalak Das headshot

Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H

by Nalak Das

We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

by Zacks Equity Research

Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.

Hologic (HOLX) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Hologic (HOLX) concluded the recent trading session at $74.53, signifying a +0.58% move from its prior day's close.

Moumi Mondal headshot

Hologic (HOLX) Moves Up 2% in a Week: Time to Consider Buying?

by Moumi Mondal

Hologic's (HOLX) fundamental strength and cheaper valuation make it a great new addition to the portfolio.

Urmimala Biswas headshot

3 Medical Instruments Picks to Navigate Industry Challenges

by Urmimala Biswas

Deteriorating geopolitical situation and supply bottlenecks mar the prospects of the Zacks Medical Instruments industry. Yet, HOLX, MASI and VCYT are worth buying based on strategic developments and fundamentals.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Here's Why You Should Retain Inari Medical (NARI) for Now

by Zacks Equity Research

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Hologic (HOLX) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Hologic (HOLX) closed at $71.65 in the latest trading session, marking a -1.15% move from the prior day.

Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Wall Street Bulls Look Optimistic About Hologic (HOLX): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Hologic (HOLX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Patterson Companies (PDCO) Q4 Earnings Miss, Sales Rise Y/Y

by Zacks Equity Research

Patterson Companies' (PDCO) fourth-quarter fiscal 2024 results reflect a year-over-year improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales improve.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.